The U.S. FDA approval of Johnson & Johnson’s Imaavy (nipocalimab-aahu) for myasthenia gravis brings the monoclonal antibody into a treatment space that teems with competition, both approved and in-development candidates. The human Fc receptor inhibitor was approved to treat generalized myasthenia gravis in patients who are 12 years and older. Patients must be anti-acetylcholine receptor [AChR] or anti-muscle-specific kinase [MuSK] antibody positive. Anti-AChR and anti-MuSK antibody-positive individuals make up more than 90% of all antibody-positive gMG patients.

Scientists at Institut Pasteur have gained new insights into how some people control HIV-1 replication after interruption of antiretroviral treatment (ART). The investigators found a fingerprint involved in long-term viral remission.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. is the latest mainland China pharmaceutical company to seek a capital raise on the Hong Kong stock exchange, winning clearance April 28 from the China Securities Regulatory Commission to float new H-shares.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. is the latest mainland China pharmaceutical company to seek a capital raise on the Hong Kong stock exchange, winning clearance April 28 from the China Securities Regulatory Commission to float new H-shares.

Research of the neuroimmune mechanisms involved in stress-related fear revealed how astrocytes interact with neurons in the amygdala. The study, led by Harvard scientists, also unveiled that this interaction recruited monocytes to the meninges during chronic stress and showed how psychedelic compounds reversed monocyte accumulation in the meninges and reduced fear behavior.

Granite Bio AG has emerged from stealth with $100 million in series A and B funding and a focus on developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions.

Repertoire Immune Medicines Inc. has entered into a collaboration and license agreement with Genentech Inc., a member of the Roche Group, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. Repertoire will use its Decode platform, which maps the immune synapse, to discover novel therapeutic targets.

Writing in Scientific Reports, researchers from the Stiftung Tieraerztliche Hochschule Hannover and collaborators present the design and evaluation of an artificial poly-epitope sequence comprising 20 potentially immunogenic conserved influenza A virus CD8+ T cell epitopes as a new vaccine candidate.